A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
NCT00807846
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)
- Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible
- ≥2 years of age and <18 years of age prior to the Baseline visit
- Body weight ≥10 kg at the Baseline visit
- Candidate for chronic NSAID therapy in the Investigator's judgment
- Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis
types of JIA
- Active systemic features over the prior 12 weeks in children with systemic Juvenile
Idiopathic Arthritis (JIA)
- Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated
arthritis should be excluded
- Subjects with active Systemic JIA should not be enrolled
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Cleveland, Ohio
- Guadalajara, Jalisco
- Tucson, Arizona
- Little Rock, Arkansas
- San Diego, California
- Hartford, Connecticut
- Washington, District of Columbia
- Delray Beach, Florida
- Delray Beach, Florida
- Miami, Florida
- Honolulu, Hawaii
- Honolulu, Hawaii
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Omaha, Nebraska
- Omaha, Nebraska
- Akron, Ohio
- Hershey, Pennsylvania
- Santiago, RM
- Concepcion, VIII Region
- San Jose,
- San Borja, Lima
- San Isidro, Lima
- Manila,
- Manila,
- Moscow,
- Moscow,
- Smolensk,
- Smolensk,
- Belgrade,
- Nis,
- Pretoria, Gauteng Province
- CH-1011 Lausanne,
- CH-8032 Zuerich,
- Kharkiv,
- Kiev,
- Kyiv,
- Simferopol,
- Zaporizhzhya,
- San Diego, California
- Hartford, Connecticut
- Delray Beach, Florida
- Miami, Florida
- St. Petersburg, Florida
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Glenview, Illinois
- Hinsdale, Illinois
- Merrillville, Indiana
- New Orleans, Louisiana
- Boston, Massachusetts
- Worcester, Massachusetts
- Omaha, Nebraska
- Livingston, New Jersey
- New Hyde Park, New York
- New York, New York
- Tulsa, Oklahoma
- Tulsa, Oklahoma
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Hershey, Pennsylvania
- Johnstown, Pennsylvania
- Lancaster, Pennsylvania
- Milwaukee, Wisconsin
- Milwaukee, Wisconsin
- Leuven,
- Rio De Janeiro, RJ
- São Paulo, SP
- São Paulo, SP
- Rio de Janeiro,
- Saskatoon, Saskatchewan
- Århus N,
- Vandoeuvre-les-nancy,
- Berlin,
- Bremen,
- Halle,
- Hamburg,
- Hannover,
- Monterrey, Nuevo Leon
- Guadalajara,
- Lima,
- Lima,
- Lima,
- Vila Nova de Famalicao,
- Moscow,
- Moscow,
- Piestany,
- Ljubljana,
- Madrid,
- Madrid,
- Valencia,
- Stockholm,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects | |||
Official Title ICMJE | A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. | |||
Brief Summary | This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Arthritis, Juvenile Rheumatoid | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 201 | |||
Original Estimated Enrollment ICMJE | 200 | |||
Actual Study Completion Date ICMJE | December 2012 | |||
Actual Primary Completion Date | December 2012 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 2 Years to 17 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Chile, Costa Rica, Peru, Philippines, Russian Federation, Serbia, South Africa, Switzerland, Ukraine, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00807846 | |||
Other Study ID Numbers ICMJE | A3191342 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |